Experimental drug aims to reverse liver damage in rare triple condition

NCT ID NCT07681089

Recruiting now Disease control Sponsor: Kiminori Kimura, MD Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: foscenvivint
What this could lead to: If successful, this could point toward a new treatment option for liver cirrhosis in people with HIV/HCV co-infection and hemophilia.
What could go wrong: This is a very small early-phase trial with only 4 participants, so results may not apply broadly. The drug may not improve liver function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hemophilia hemophilia A hepatitis C virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Locations

Hokkaido University Hospital
RECRUITING

Sapporo, Hokkaido, 060-8648, Japan
National Hospital Organization Osaka National Hospital
RECRUITING

Osaka, Osaka, 540-0006, Japan
Tokyo Metropolitan Komagome Hospital
RECRUITING

Bunkyo-Ku, Tokyo, 113-8677, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.